Buy & Sell Twist Bioscience Corp (TWST) – Twist Bioscience Corp Price Today
Aura AI Summary
Key Stats
- $3.65BMarket Cap
- HealthSector
- -23.4%3M Drawdown
- $3.57BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 29 daysTypical Hold Time
Twist Bioscience Corp (TWST) is currently valued at a market capitalization of $3.65B, with an enterprise value of $3.57B. Over the past 52 weeks, Twist Bioscience Corp has traded between a low of $24.16 and a high of $63.2, highlighting its annual price range. Over the past three months, Twist Bioscience Corp has recorded a drawdown of -23.4%, reflecting recent price volatility. On average, investors hold Twist Bioscience Corp for approximately 29 days, indicating typical investor behavior on the platform.
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Most Recent News
US Vice President JD Vance meets Qatar PM to discuss Iran talks and regional stability amid Middle East tensions
US Vice President JD Vance met with Qatar Prime Minister Sheikh Mohammed bin Abdulrahman al-Thani in Washington to discuss ongoing Iran negotiations, US-Qatar relations, and regional stability amid fragile ceasefire conditions. The talks come as the ...
Lime, backed by Uber, files for IPO after 29% revenue growth in FY25, planning Nasdaq listing.
Lime, the electric bike and scooter company supported by Uber, filed for a U.S. IPO, reporting a 29.1% revenue increase to $886.7 million in fiscal year 2025. The company operates in 230 cities across 29 countries and has achieved positive free cash ...
Blackstone maintains buy rating with strong Q1 inflows, earnings growth, and AI expansion plans.
Blackstone retains a buy rating as its fundamentals remain strong despite recent concerns in private credit and stock underperformance since January. The company saw inflows rise to $68.5 billion in Q1, with a 22% year-over-year increase in Credit & ...
